MicrobioTx launches IBS Risk Score to enable early detection of gut disorder

The launch coincides with IBS Awareness Month in April

MicrobioTx has announced the launch of its Irritable Bowel Syndrome (IBS) Risk Score, a predictive solution designed to assess an individual’s likelihood of developing IBS using advanced microbiome and metabolite analysis.

The launch coincides with IBS Awareness Month in April.

IBS remains one of the most common yet underdiagnosed gastrointestinal conditions in India, affecting an estimated 4–8% of the population—roughly 40–80 million people. With no definitive diagnostic test, IBS is typically identified through symptoms such as abdominal pain, bloating, cramping, and altered bowel habits, including diarrhea, constipation, or both. This symptom-based approach often leads to delays in diagnosis and a significant hidden disease burden, as many patients do not seek timely medical care.

MicrobioTx’s IBS Risk Score leverages gut microbiome profiling alongside metabolite analysis—biological signals released by microbes into the bloodstream—to deliver deeper insights into gut health. By identifying patterns linked to IBS, the tool aims to support early risk detection and enable more informed clinical decision-making.

The company’s latest offering marks a shift from reactive diagnosis to proactive risk assessment. It builds on MicrobioTx’s ongoing research in microbiome science and a recently concluded clinical study conducted in collaboration with Maulana Azad Medical College. The study validated the high accuracy of its Gut Function Test (GFT) for Indian IBS patients, demonstrating strong predictive capabilities in identifying both general and IBS-specific microbiome imbalances.

“IBS is a prevalent and underdiagnosed condition. Gut dysbiosis is an important contributing factor in its development and is a potential therapeutic opportunity,” said Dr Ujjwal Sonika, Professor of Gastroenterology at Maulana Azad Medical College and principal investigator for the study.

The study data has also informed the development of the IBS Risk Score, which analyzes an individual’s microbiome and metabolic profile to assess whether it aligns with patterns associated with IBS. This can help clinicians better evaluate disease risk and tailor early interventions.

The launch reinforces MicrobioTx’s focus on delivering accessible, science-backed microbiome solutions aimed at improving gut health outcomes.